{'fraction_non_alphanumeric': 0.024349979364424266, 'fraction_numerical': 0.005777961205117622, 'mean_word_length': 5.945558739255015, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Percutaneous vertebroplasty combined with concurrent and non‐concurrent use of zoledronic acid in the treatment of osteoporotic vertebral compression fractures: a 1‐year follow‐up comparison

BACKGROUND: For osteoporotic vertebral compression fractures, bone cement injection alone cannot effectively relieve osteoporosis. Therefore, anti‐osteoporosis treatment is necessary, and the timing for anti‐osteoporosis treatment is still pending. OBJECTIVE: To compare the clinical outcomes of percutaneous vertebroplasty combined with concurrent and non‐concurrent use of zoledronic acid in the treatment of osteoporotic vertebral compression fractures based on a 1 ‐year follow‐up visit. METHODS: Sixty patients with osteoporotic vertebral compression fractures were enrolled, 30 cases in group A who were treated with vertebroplasty combined with zoledronic acid, while the other 30 cases in group B who were treated with vertebroplasty and given zoledronic acid Injection at 1 month after vertebroplasty. Both groups were given calcium preparation and vitamin D treatment. RESULTS AND CONCLUSION: Vertebral height and Cobb angle in the two groups were significantly improved after treatment compared with the baseline. Visual Analogue Scale scores and Oswestry disability index were reduced in the two groups after treatment compared with the baseline. Increased bone mineral density of the hip, reduced levels of serum procollagen type I carboxy‐terminal extension peptide (PINP) and &bgr;‐C‐terminal cross‐linking telopeptide of type I collagen (&bgr;‐CTX), and increased 25‐hydroxy vitamin D were also found in the two groups after treatment compared with the baseline. However, there was no significant difference in the serum level of parathyroid hormone before and after treatment. Compared with the non‐concurrent group, the concurrent groups had lower scores on the Visual Analogue Scale scores and Oswestry disability index at 1 month and 1 year after treatment, higher bone mineral density of the hip, lower levels of PINP and &bgr;‐CTX, and higher level of 25‐hydroxy vitamin D at 1 year after treatment. These findings indicate that percutaneous vertebroplasty combined with concurrent zoledronic acid can effectively treat osteoporotic vertebral compression fractures, restore vertebral height, relieve pain, elevate bone mineral density and improve bone metabolism, which is a method available for clinical use.